Incruse Eclipses Spiriva

CareOregon now requires the use of Incruse Ellipta (umeclidinium) for patients with COPD who need a Long-Acting Muscarinic Antagonist (LAMA). This change became effective April 1 on the Medicaid (OHP) formulary.  Spiriva (tiotropium) will remain covered for existing users as long as they remain on therapy consistently.  If there is a 3-month gap between Spiriva fills, the prescription will reject at the pharmacy and Incruse Ellipta will be required. Spiriva Respimat remains on the formulary with PA for its asthma indication. In a recent MEDS Ed seminar on COPD, several attendees found Incruse Ellipta to be far easier to use than Spiriva Respimat. While Incruse Ellipta is relatively new to the market, CareOregon believes it will be a simple transition due to its ease of administration. Similar to Spiriva, it is only dosed once per day. While there are no studies that directly compare Spiriva and Incruse, they are thought to be equally effective.

If COPD therapy needs to be advanced due to worsening disease, the Ellipta delivery device is also covered on the Medicaid formulary with Anoro Ellipta (umeclidinium/vilanterol) and Trelegy Ellipta (umeclidium/vilanterol/fluticasone).